यूरोपीय संघ - एस्टोनियाई - EMA (European Medicines Agency)

accord healthcare s.l.u. - icatibant acetate - angioödeem, pärilik - other hematological agents - icatibant accord is indicated for symptomatic treatment of acute attacks of hereditary angioedema (hae) in adults, adolescents and children aged 2 years and older, with c1 esterase inhibitor deficiency.

एस्टोनिया - एस्टोनियाई - Ravimiamet

septodont - neomütsiin+bensokaiin - hambapulk - 15400rÜ+5mg 50tk; 15400rÜ+5mg 200tk

एस्टोनिया - एस्टोनियाई - Ravimiamet

teva b.v. - ikatibant - süstelahus süstlis - 10mg 1ml 3ml 1tk; 10mg 1ml 3ml 3tk

एस्टोनिया - एस्टोनियाई - Ravimiamet

fresenius kabi polska sp. z o.o. - ikatibant - süstelahus süstlis - 30mg 3ml 3ml 1tk; 30mg 3ml 3ml 3tk

एस्टोनिया - एस्टोनियाई - Ravimiamet

auxilia pharma oÜ - ikatibant - süstelahus süstlis - 30mg 3ml 3ml 1tk; 30mg 3ml 3ml 3tk

यूरोपीय संघ - एस्टोनियाई - EMA (European Medicines Agency)

pierre fabre medicament - milnatsipraan - fibromüalgia

यूरोपीय संघ - एस्टोनियाई - EMA (European Medicines Agency)

ipsen pharma - cabozantinib (s)-malate - carcinoma, renal cell; carcinomas, hepatocellular - antineoplastilised ained - renal cell carcinoma (rcc)cabometyx is indicated as monotherapy for the treatment of advanced renal cell carcinoma (rcc):in treatment-naïve adults with intermediate or poor risk,in adults following prior vascular endothelial growth factor (vegf)-targeted therapy. cabometyx, in combination with nivolumab, is indicated for the first-line treatment of advanced renal cell carcinoma in adults. hepatocellular carcinoma (hcc)cabometyx is indicated as monotherapy for the treatment of hepatocellular carcinoma (hcc) in adults who have previously been treated with sorafenib.

यूरोपीय संघ - एस्टोनियाई - EMA (European Medicines Agency)

teva b.v. - salmeterol, fluticasone propionaat - pulmonary disease, chronic obstructive; asthma - ravimid hingamisteede obstruktiivsete haiguste, - airexar spiromax on näidustatud kasutamiseks täiskasvanutel vanuses 18 aastat ja vanemad ainult. asthmaairexar spiromax is indicated for the regular treatment of patients with severe asthma where use of a combination product (inhaled corticosteroid and long-acting β2 agonist) is appropriate:- patients not adequately controlled on a lower strength corticosteroid combination productor- patients already controlled on a high dose inhaled corticosteroid and long-acting β2 agonist. krooniline obstruktiivne kopsuhaigus (copd)airexar spiromax on näidustatud sümptomaatiline ravi patsientidel, kellel copd), koos fev1.

एस्टोनिया - एस्टोनियाई - Ravimiamet

lfb biomedicaments - von willebrandi faktor - süstelahuse pulber ja lahusti - 2000rÜ 20ml 1tk

एस्टोनिया - एस्टोनियाई - Ravimiamet

lfb biomedicaments - von willebrandi faktor - süstelahuse pulber ja lahusti - 1000rÜ 10ml 1tk